Skip to main content
TScan Therapeutics, Inc. (TCRX)
NASDAQ: TCRX · Real-Time Price · USD
1.610
+0.010 (0.63%)
Jun 12, 2025, 4:00 PM - Market closed

Revenue by Product

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
T Cell Receptor-engineered T Cell
2.82M
Log In
Log In
Log In
Log In
T Cell Receptor-engineered T Cell Growth
-86.62%
Log In
Log In
Log In
Log In

Revenue by Geography

Fiscal year is January - December.
Fiscal Year
 FY 2024 FY 2023 FY 2022 FY 2021 FY 2020
Period Ending
 Dec '24 Dec '23 Dec '22 Dec '21 Dec '20
United States
2.82M
Log In
Log In
Log In
Log In
United States Growth
-86.62%
Log In
Log In
Log In
Log In